NCT03459443终止2 期
An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Change From Baseline In Composite Biopsy Score At End Of Initial 12-Month Treatment Period
研究概览
简要总结
The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.
详细描述
This was an open-label study to evaluate the efficacy of treatment with danicopan in participants 12 years of age or older with biopsy-confirmed C3G or IC-MPGN who had not undergone renal transplantation. All participants were to receive active treatment with danicopan for approximately 40 months. The starting dosage was to be 100 mg TID, and after 2 weeks, the dosage was to be increased to 200 mg TID for participants with body weight ≥ 60 kg or 150 mg TID for participants with body weight < 60 kg. Planned enrollment was approximately 20 participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 12 years of age
- •Completion of the ACH471-201 clinical study OR diagnosed with biopsy-confirmed primary C3G or IC-MPGN
- •If a pre-treatment biopsy is obtained, or if a historical biopsy is available for review, it must have no more than 50% global fibrosis and no more than 50% of glomeruli with cellular crescents
- •Clinical evidence of ongoing disease based on significant proteinuria (defined as ≥500 mg/day of protein in a 24-hour urine) attributable to C3G disease or IC-MPGN in the opinion of the principal investigator (PI), and present prior to study entry and confirmed during Screening
- •If on corticosteroids, anti-hypertensive medications, anti-proteinuric medications (for example, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), or mycophenolate mofetil, must be on a stable dose for at least 2 weeks prior to screening
- •Female participants must use an acceptable method birth control to prevent pregnancy during the clinical study and for 30 days after the last dose of study medication
- •Male participants must use highly effective birth control with a female partner to prevent pregnancy during the clinical study and for 90 days after the last dose of study medication
- •Must be up-to-date on routine vaccinations, or willing to be brought up-to-date, based on local guidelines
- •Must have access to emergency medical care
- •Key Exclusion Criteria
- •Have a history of a major organ transplant (for example, heart, lung, kidney, or liver) or hematopoietic stem cell/marrow transplant
- •Have a history or presence of any clinically relevant co-morbidities that would make the participant inappropriate for the study (for example, a comorbidity that is likely to result in deterioration of the participant's condition, affect the participant's safety during the study, or confound the results of the study), in the opinion of the PI
- •Have an eGFR <30 milliliter/minute/1.73 m^2 at the time of screening or at any time over the preceding 4 weeks
- •Is a renal transplant recipient or receiving renal replacement therapy
- •Have other renal diseases that would interfere with the interpretation of the study
- •Have evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G or IC-MPGN is secondary
- •Have been diagnosed with or show evidence of hepatobiliary cholestasis
- •Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of ACH-0144471 administration or participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of ACH-0144471 administration
- •Have a history of febrile illness, a body temperature >38°Celsius, or other evidence of a clinically significant active infection, within 14 days prior to danicopan administration
- •Have evidence of human immunodeficiency virus, hepatitis B infection, or active hepatitis C infection at Screening
- •Have a history of meningococcal infection within the prior year
- •Have a history of hypersensitivity reactions to commonly used antibacterial agents, including beta-lactams, penicillin, aminopenicillins, fluoroquinolones, cephalosporins, and carbapenems, which, in the opinion of the investigator and/or an appropriately qualified immunology or infectious disease expert, would make it difficult to properly provide either empiric antibiotic therapy or treat an active infection.
- •Have participated in a clinical study in which an investigational drug was given within 30 days, or within 5 half-lives of the investigational drug, whichever is longer, prior to the first dose of ACH-0144471
- •Have received eculizumab at any dose or interval within the past 50 days prior to the first dose of ACH-0144471
- •Have received tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471
- •Have a 12-lead electrocardiogram (ECG) with a QT interval Fridericia correction formula >450 millisecond (msec) for males or >470 msec for females, or have ECG findings which, in the opinion of the PI, could put the participant at undue risk
- •Have received any drug known to prolong the corrected QT interval within 2 weeks of the first dose of ACH-0144471 and which, in the opinion of the PI, could put the participant at undue risk
- •Have any of the following laboratory abnormalities at screening:
- •Alanine transaminase > upper limit of normal (ULN)
- •Aspartate aminotransferase > ULN
- •Absolute neutrophil counts <1,000/microliter
- •Total bilirubin >1.5* ULN
- •Indirect bilirubin > ULN
- •Any laboratory abnormality that, in the opinion of the PI, would make the participant inappropriate for the study
- •Unwilling or unable to comply with the study protocol for any reason
排除标准
- 未提供
研究组 & 干预措施
Danicopan
Experimental
Danicopan was to be administered to participants with C3G or IC-MPGN at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then the dosage was to be increased to 200 mg TID for the remainder of the study.
干预措施: Danicopan (Drug)
结局指标
主要结局
Change From Baseline In Composite Biopsy Score At End Of Initial 12-Month Treatment Period
时间窗: Baseline, end of initial 12-Month Treatment Period
The composite biopsy score was based on a score incorporating changes in the activity index, glomerular C3c staining, and glomerular macrophage infiltration at the end of the initial 12 months of treatment. The composite renal biopsy index scoring system ranged from 0 to 21, with higher scores indicating worse outcomes.
Participants With Reduction In Proteinuria At End Of Initial 12-Month Treatment Period
时间窗: Baseline, end of initial 12-Month Treatment Period
Proteinuria reduction was defined as ≥30% decrease from baseline based on 24-hour urine protein (mg/day).
次要结局
- Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period(Baseline, end of initial 12-Month Treatment Period)
- Change From Baseline In eGFR At End Of Initial 12-Month Treatment Period(Baseline, end of initial 12-Month Treatment Period)
- Participants With Significant Improvement In eGFR Relative To Baseline At End Of Initial 12-Month Treatment Period(Baseline, end of initial 12-Month Treatment Period)
- Percent Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period(Baseline, end of initial 12-Month Treatment Period)
- Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To End Of Initial 12-Month Treatment Period(End of initial 12-Month Treatment Period)
- Change From Baseline In Measured GFR At The End Of The Initial 12-Month Treatment Period(End of initial 12-Month Treatment Period)
- Change From Baseline in eGFR Over 12 Months of Treatment For Participants Meeting eGFR Inclusion Criteria(End of initial 12-Month Treatment Period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT03053102Alexion Pharmaceuticals, Inc.10
已完成
2 期
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in AdolescentsGastroesophageal Reflux DiseaseNCT01642602Takeda104
已完成
1 期
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid TumorsSolid TumourNCT01300468Nerviano Medical Sciences38
已完成
2 期
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.Neoplasms, BreastMetastatic Breast CancerNCT00051103GlaxoSmithKline
已完成
2 期
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabParoxysmal Nocturnal Hemoglobinuria (PNH)NCT03472885Alexion Pharmaceuticals, Inc.12